PKO Investment Management Joint Stock Co Takes $3.73 Million Position in DexCom, Inc. (NASDAQ:DXCM)

PKO Investment Management Joint Stock Co purchased a new position in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 48,000 shares of the medical device company's stock, valued at approximately $3,733,000.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in DXCM. Norges Bank purchased a new stake in DexCom in the 4th quarter valued at approximately $385,367,000. Congress Asset Management Co. boosted its holdings in DexCom by 5,456.9% in the 4th quarter. Congress Asset Management Co. now owns 1,356,941 shares of the medical device company's stock valued at $105,529,000 after purchasing an additional 1,332,522 shares in the last quarter. Fisher Funds Management LTD purchased a new stake in DexCom in the 4th quarter valued at approximately $96,507,000. Woodline Partners LP purchased a new stake in DexCom in the 4th quarter valued at approximately $63,338,000. Finally, Northern Trust Corp boosted its holdings in DexCom by 22.2% in the 4th quarter. Northern Trust Corp now owns 4,146,249 shares of the medical device company's stock valued at $322,454,000 after purchasing an additional 753,857 shares in the last quarter. Hedge funds and other institutional investors own 97.75% of the company's stock.

Insider Buying and Selling at DexCom

In other news, EVP Jereme M. Sylvain sold 7,000 shares of the business's stock in a transaction on Monday, March 10th. The shares were sold at an average price of $73.83, for a total transaction of $516,810.00. Following the completion of the sale, the executive vice president now directly owns 135,482 shares of the company's stock, valued at $10,002,636.06. The trade was a 4.91% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Kevin R. Sayer sold 32,498 shares of the business's stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total transaction of $2,287,209.24. Following the sale, the chief executive officer now directly owns 372,029 shares of the company's stock, valued at $26,183,401.02. This represents a 8.03% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 83,110 shares of company stock worth $6,103,505. Insiders own 0.32% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on the company. Piper Sandler lowered their price objective on DexCom from $100.00 to $90.00 and set an "overweight" rating on the stock in a report on Friday, May 2nd. Robert W. Baird reduced their price target on shares of DexCom from $115.00 to $105.00 and set an "outperform" rating for the company in a research report on Friday, May 2nd. Canaccord Genuity Group lifted their price target on shares of DexCom from $103.00 to $106.00 and gave the company a "buy" rating in a research report on Friday, May 2nd. Cfra Research upgraded shares of DexCom to a "hold" rating in a research report on Friday, March 21st. Finally, Mizuho began coverage on shares of DexCom in a research report on Thursday, April 10th. They set an "outperform" rating and a $85.00 price target for the company. Five analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and three have assigned a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $98.32.

DexCom Trading Up 1.3%

DXCM traded up $1.10 during trading on Friday, hitting $85.96. The company's stock had a trading volume of 4,257,051 shares, compared to its average volume of 4,363,381. The firm's 50 day moving average price is $74.67 and its 200-day moving average price is $78.72. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.47 and a quick ratio of 1.28. The stock has a market cap of $33.71 billion, a PE ratio of 60.11, a PEG ratio of 2.30 and a beta of 1.43. DexCom, Inc. has a twelve month low of $57.52 and a twelve month high of $120.48.

DexCom (NASDAQ:DXCM - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The medical device company reported $0.32 earnings per share for the quarter, missing the consensus estimate of $0.33 by ($0.01). The business had revenue of $1.04 billion during the quarter, compared to analyst estimates of $1.02 billion. DexCom had a net margin of 14.29% and a return on equity of 30.14%. The company's revenue was up 12.5% on a year-over-year basis. During the same quarter last year, the firm posted $0.32 earnings per share. On average, analysts expect that DexCom, Inc. will post 2.03 earnings per share for the current year.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.